Overview

Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca